Genital Diseases, Male  >>  carotuximab IV (ENV-105)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
carotuximab IV (ENV-105) / Kairos Pharma
NCT01090765: A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)

Completed
1/2
21
US
TRC105
National Cancer Institute (NCI)
Prostate Cancer, Metastatic Castrate Resistant Prostate Cancer
04/14
04/15

Download Options